Chronic kidney disease
Conditions
Interventions
ESA group: Erythropoietin treatment group:NA
HFI-PHI group: treatment group using roxatidine or enadoxine:NA
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Inclusion criteria: Patients who visited the outpatient or inpatient department of Nephrology at West China Hospital of Sichuan University from November 1, 2025 to November 30, 2027 and were diagnosed with chronic kidney disease-related anemia according to the diagnostic criteria defined in the "Clinical Practice Guidelines for the Diagnosis and Treatment of Renal Anemia in China"; 2. Age of 18 years or above, regardless of gender, race, etc.; 3. Intending to receive ESA or HIF-HIP treatment for chronic kidney disease-related anemia; 4. Patients who can be followed up regularly, that is, at least once every 3 months within one year after diagnosis until the completion of one-year follow-up (prospective cohort).
Exclusion criteria
Exclusion criteria: 1. History of blood transfusion within 8 weeks; 2. Scheduled for elective surgery; 3. Active infection or active bleeding; 4. Severe liver disease, malignant tumor, hematological disorder, mental abnormality; pregnant or lactating period; 5. Patients with acute cardiovascular or cerebrovascular diseases; 6. Incomplete medical records; 7. Other reasons assessed by the researcher as not suitable for inclusion in the study. 8. Patients who cannot be followed up regularly.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hemoglobin; | — |
Secondary
| Measure | Time frame |
|---|---|
| red blood cell count;hematocrit;serum ferritin;serum iron;total iron binding capacity; transferrin saturation; triglycerides;cholesterol; | — |
Countries
China
Contacts
Public ContactWei Qin
Division of Nephrology, Department of Medicine, West China Hospital of Sichuan University,
Outcome results
None listed